淀粉样蛋白影像的临床应用与效用
本文综述淀粉样蛋白PET显像的临床应用与效用。目前已有3种淀粉样蛋白PET示踪剂获批并商业化用于临床,可准确在体内检测淀粉样斑块。现有数据表明约30%病例诊断改变、约60%诊断信心提高、约60%患者管理改变、约40%用药改变,但患者结局与成本效益的初步模拟研究结果尚需前瞻性临床试验确认。
要点
- 3种淀粉样蛋白PET示踪剂已获批并商业化用于临床。
- 约30%病例诊断改变,约60%诊断信心提高,约60%患者管理改变,约40%用药改变。
- 患者结局与成本效益的初步模拟结果尚需前瞻性临床试验确认。
核心结论
- 淀粉样蛋白影像的临床应用正在研究中,现有数据指向该技术具有相关的临床效用。
- 正在进行的研研究将确定这种准确、无创的淀粉样斑块负荷检测方法是否转化为认知障碍受试者的获益。
研究设计与样本
- 本文为综述,汇总淀粉样蛋白影像临床使用与效用的当前知识。
主要发现
- 目前有3种淀粉样蛋白PET示踪剂获批并商业化用于临床,可在体内准确检测淀粉样斑块,淀粉样斑块是阿尔茨海默病的标志之一。
- 淀粉样蛋白影像的临床应用适当使用标准已建立,大多数现有数据指向其有效性。
- 视觉淀粉样蛋白图像分析高度标准化。
- 许多认知障碍受试者希望获知淀粉样蛋白影像结果,且在向披露结果的临床医生提供适当教育后似乎安全。
- 关于临床效用,越来越多的证据指向:约30%病例诊断改变、约60%病例诊断信心提高、约60%病例患者管理改变、约40%病例用药改变;淀粉样蛋白影像结果似乎对照护者也有相关影响。
关键数值与推荐
- 淀粉样蛋白影像的临床应用适当使用标准已建立,大多数现有数据指向其有效性。
- 视觉淀粉样蛋白图像分析高度标准化。
- 约30%病例经淀粉样蛋白影像诊断改变。
- 约60%病例诊断信心提高。
- 约60%病例患者管理改变,约40%病例用药改变。
临床怎么用
- 许多认知障碍受试者希望获知淀粉样蛋白影像结果,在向披露结果的临床医生提供适当教育后似乎安全。
- 初步模拟研究指向淀粉样蛋白影像对患者结局的潜在正面影响及成本效益,但这些特征尚需前瞻性临床试验确认。
- 尚需更多工作以确定淀粉样蛋白影像在轻度认知障碍受试者中的临床效用,以及与其他阿尔茨海默病生物标志物比较或联合使用时的临床效用。
局限性
- 患者结局与成本效益的初步模拟研究结果尚需前瞻性临床试验确认。
- 尚需更多工作以确定淀粉样蛋白影像在轻度认知障碍受试者中的临床效用,以及与其他阿尔茨海默病生物标志物比较或联合使用时的临床效用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Currently, 3 amyloid PET tracers are approved and commercially available for clinical use. They allow for the accurate in vivo detection of amyloid plaques, one hallmark of Alzheimer disease. Here, we review the current knowledge on the clinical use and utility of amyloid imaging. Appropriate use criteria for the clinical application of amyloid imaging are established, and most currently available data point to their validity. Visual amyloid image analysis is highly standardized. Disclosure of amyloid imaging results is desired by many cognitively impaired subjects and seems to be safe once appropriate education is delivered to the disclosing clinicians. Regarding clinical utility, increasing evidence points to a change in diagnosis via amyloid imaging in about 30% of cases, to an increase in diagnostic confidence in about 60% of cases, to a change in patient management in about 60% of cases, and specifically to a change in medication in about 40% of cases. Also, amyloid imaging results seem to have a relevant impact on caregivers. Further, initial simulation studies point to a potential positive effect on patient outcome and to cost effectiveness of amyloid imaging. These features, however, will require confirmation in prospective clinical trials. More work is also required to determine the clinical utility of amyloid imaging specifically in subjects with mild cognitive impairment and in comparison with or in conjunction with other Alzheimer disease biomarkers. In summary, the clinical use of amyloid imaging is being studied, and the currently available data point to a relevant clinical utility of this imaging technique. Ongoing research will determine whether this accurate and noninvasive approach to amyloid plaque load detection will translate into a benefit to cognitively impaired subjects.
引用
- Barthel H, Sabri O. Clinical Use and Utility of Amyloid Imaging. J Nucl Med. 2017. PMID: 28818990. doi:10.2967/jnumed.116.185017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。